Inhalation exposure of nano diamond induced oxidative stress in lung,heart and brain

1. Today, diamond nanoparticles have several industrial applications. Nano diamond (ND) as a carbon allotrope diffuses in the air easily during producing and processing procedures.

2. In this study, we investigated sub-acute exposed to ND at the exposure chamber in mice. The animals were divided into two groups (control and exposed group to ND at the concentration of 3?µg/m³ for 3?h/day, 5?days/week for 30?days) in a whole-body inhalation chamber.

3. Our results showed that exposure to ND induced the hematological and biochemical changes. The target organs for ND were the lungs, brain and heart in the mice, respectively. Also, ND increased reactive oxygen species (ROS) generation, lipid peroxidation (LPO), the collapse of mitochondrial membrane potential (MMP), decreased a level of reduced glutathione (GSH) and finally increased a level of glutathione disulfide (GSSG) in lung, brain and heart tissues. Our results suggest that exposure to ND can induce oxidative stress in the tissue mentioned.

4. These results suggest that exposure of researchers and workers with diamond nanoparticles probably increase a risk of respiratory, cardiovascular and cerebral disorders through oxidative stress. However, good ventilation, appropriate personal protective equipment and using of anti-oxidant compounds in daily diet of worker are suggested.     

Toxicological and ecotoxicological properties of gas-to-liquid (GTL) products. 2. Ecotoxicology

Gas-to-liquid (GTL) products are synthetic hydrocarbons produced from natural gas using a catalytic process known as the Fischer–Tropsch process. This process yields a synthetic crude oil that consists of saturated hydrocarbons which can subsequently be refined to a range of products analogous to those obtained from petroleum refining. However, in contrast to their petroleum-derived analogs, GTL products are essentially free of unsaturated or aromatic compounds and do not contain any sulfur-, oxygen-, or nitrogen-containing compounds. Under new chemical substance notification requirements, an extensive testing program covering the entire portfolio of GTL products has been undertaken to assess their hazardous properties to human health and environment. The results of these studies have been summarized in a two-part review. Part 1 provides an overview of the mammalian toxicity hazardous properties of the various GTL products. This second part of the review focuses on the aquatic, sediment, terrestrial, and avian toxicity studies which assess the ecotoxicological hazard profile of the GTL products. Many challenges were encountered during these tests relating to dosing, analysis and interpretation of results. These are discussed with the intent to share experiences to help inform and shape future regulatory mandates for testing of poorly soluble complex substances. As was the case with the mammalian toxicology review, there were a few cases where adverse effects were found, but overall the GTL products were found to exert minimal adverse ecotoxicological effects and these were less severe than effects observed with their conventional, petroleum-derived analogs.     

纳米硫化镉呼吸道亚慢性暴露对雄性大鼠的生殖毒性

目的探讨纳米硫化镉(CdS)对大鼠睾丸的氧化损伤及对精子的影响。方法 32只雄性清洁级SD大鼠随机分为对照组(蒸馏水)、10 mg/kg、20 mg/kg和30 mg/kg的纳米CdS组,每组8只。采用肺灌注方法染毒,2次/周,持续染毒12周。计算睾丸脏器系数,测定睾丸组织中超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)活力和丙二醛(MDA)含量,观察精子数量、畸形率、活动度和睾丸的病理学变化。结果与对照组相比,30 mg/kg染毒组精子数量、精子活动度降低,10、20、30 mg/kg染毒组精子畸形率增高(P<0.05)。与对照组相比,30 mg/kg染毒组的大鼠睾丸SOD、GSH-Px活力降低(P<0.05),10、20、30 mg/kg染毒组的大鼠睾丸MDA含量增高(P<0.05)。染毒组生精小管内生精细胞脱落,层次减少,各级生精细胞排列紊乱,管内生精细胞疏松、排列紊乱、上皮变薄,管腔内可见脱落的精子细胞。结论纳米硫化镉经呼吸道染毒可致大鼠睾丸病理改变,氧化损伤,并且引起精子数量减少,活动度降低,畸形率增加。     

Nrf2信号通路在锰致雄性小鼠生殖毒性中的作用

目的研究锰对雄性小鼠睾丸Nrf2信号通路的影响,探索锰致雄性生殖障碍的机制。方法将48只雄性昆明小鼠随机分为对照组、高锰组、高锰+叔丁基对苯二酚(t BHQ)干预组和高锰+异烟肼(INH)干预组。对照组、高锰组皮下注射生理盐水,t BHQ干预组皮下注射50 mg/kg t BHQ,INH干预组皮下注射100 mg/kg INH。2 h后对照组腹腔注射生理盐水,其余三组腹腔注射50 mg/kg Mn Cl2。注射容量均5 ml/kg,持续4周。HE染色观察小鼠睾丸组织形态改变;Western blotting测定睾丸组织内Nrf2、SOD2及GPx-1的蛋白表达水平。结果与对照组比较,高锰组小鼠睾丸组织形态出现损伤;与高锰组比较,t BHQ干预组小鼠睾丸组织形态损伤出现恢复;INH干预组损伤加剧。与对照组比较,高锰组睾丸组织内Nrf2、SOD2及GPx-1的蛋白水平分别下降49.14%、49.42%、39.06%;与高锰组比较,t BHQ干预使上述指标恢复,Nrf2、SOD2及GPx-1分别升高35.77%、31.77%、41.52%;INH干预使之加剧,Nrf2、SOD2及GPx-1分别下降32.71%、14.65%、40.31%。结论锰暴露可通过干扰Nrf2信号通路,造成睾丸组织病理损伤,产生生殖毒性。     

SD大鼠神经干细胞评价药物神经毒性模型研究

目的：应用SD大鼠神经干细胞评价药物的神经毒性,为新药早期筛选和临床前安全性评价提供体外替代方法。方法：体外培养SD大鼠神经干细胞,传代后得到稳定的第二代神经球。以已知具有神经毒性的长春新碱、顺铂、瑞芬太尼、丙泊酚注射液、丙戊酸钠、苯妥英钠、丙烯酰胺、乙醇、氧化铁纳米粒子作为神经毒性阳性物质,以培养基作为神经毒性空白对照品;以没有神经毒性且具有促进神经细胞生长的神经生长因子作为检测模型的敏感性;以验证SD大鼠神经干细胞模型对神经毒性药物的检出能力。结果：长春新碱、顺铂、丙泊酚注射液、苯妥英钠、丙烯酰胺、氧化铁纳米粒子可引起全部或部分神经球解离破碎,神经干细胞坏死。顺铂、丙戊酸钠和苯妥英钠可见显著性的抑制神经球聚集。长春新碱、顺铂、瑞芬太尼、氧化铁纳米粒子、丙泊酚注射液、丙戊酸钠、苯妥英钠、丙烯酰胺、乙醇均表现剂量相关性的神经干细胞增殖毒性作用。神经生长因子可见促进神经球聚集及神经干细胞增殖。结论：本文以SD大鼠神经干细胞模型,以神经干细胞体外生长发育指标,验证了已知神经毒性抗肿瘤药物、麻醉剂、抗癫痫药物等的神经毒性特征。评价结果与这些药物已知的神经毒性作用特点一致,该评价方法可作为药物神经毒性临床前安全性评价研究的体外替代试验。     

Halloysite nanotubes‐induced Al accumulation and oxidative damage in liver of mice after 30‐day repeated oral administration

Halloysite (Al₂Si₂O₅(OH)₄·nH₂O) nanotubes (HNTs) are natural clay materials and widely applied in many fields due to their natural hollow tubular structures. Many in vitro studies indicate that HNTs exhibit a high level of biocompatibility, however the in vivo toxicity of HNTs remains unclear. The objective of this study was to assess the hepatic toxicity of the purified HNTs in mice via oral route. The purified HNTs were orally administered to mice at 5, 50, and 300 mg/kg body weight (BW) every day for 30 days. Oral administration of HNTs stimulated the growth of the mice at the low dose (5 mg/kg BW) with no liver toxicity, but inhibited the growth of the mice at the middle (50 mg/kg BW) and high (300 mg/kg BW) doses. In addition, oral administration of HNTs at the high dose caused Al accumulation in the liver but had no marked effect on the Si content in the organ. The Al accumulation caused significant oxidative stress in the liver, which induced hepatic dysfunction and histopathologic changes. These findings demonstrated that Al accumulation‐induced oxidative stress played an important role in the oral HNTs‐caused liver injury.     

Naringenin (4,5,7‐trihydroxyflavanone) suppresses the development of precancerous lesions via controlling hyperproliferation and inflammation in the colon of Wistar rats

Colon cancer is a world‐wide health problem and one of the most dangerous type of cancer, affecting both men and women. Naringenin (4, 5, 7‐trihydroxyflavanone) is one of the major flavone glycoside present in citrus fruits. Naringenin has long been used in Chinese's traditional medicine because of its exceptional pharmacological properties and non‐toxic nature. In the present study, we investigated the chemopreventive potential of Naringenin against 1,2‐dimethyhydrazine (DMH)‐induced precancerous lesions, that is, aberrant crypt foci (ACF) and mucin depleted foci (MDF), and its role in regulating the oxidative stress, inflammation and hyperproliferation, in the colon of Wistar rats. Animals were divided into five groups. In groups 3‐5, Naringenin was administered at the dose of 50 mg/kg b. wt. orally while in groups 2‐4, DMH was administered subcutaneously in the groin at the dose of 20 mg/kg b. wt. once a week for first 5 weeks and animals were euthanized after 10 weeks. Administration of Naringenin ameliorated the development of DMH‐induced lipid peroxidation, ROS formation, precancerous lesions (ACF and MDF) and it also reduced the infiltration of mast cells, suppressed the immunostaining of NF‐κB‐p65, COX‐2, i‐NOS PCNA and Ki 67 Naringenin treatment significantly attenuated the level of TNF‐α and it also prevented the depletion of the mucous layer. Our findings suggest that Naringenin has strong chemopreventive potential against DMH‐induced colon carcinogenesis but further studies are warranted to elucidate the precise mechanism of action of Naringenin.     

Abemaciclib for the treatment of breast cancer

Introduction: There have been numerous clinical trials of CDK4/6 inhibitors performed on various carcinomas including breast cancer. One such inhibitor tested and which has ongoing clinical trials for breast cancer is abemaciclib. Abemaciclib is a molecular-targeted agent that targets basic cell cycle regulatory mechanisms.

Areas covered: This review discusses the available clinical data and ongoing clinical trials of abemaciclib in breast cancer.

Expert opinion: Abemaciclib has demonstrated a clear anti-tumour effect and manageable toxicity against HR-positive, HER2-negative breast cancer in many clinical trials and is expected to be an important standard therapy. However, currently, besides oestrogen receptor expression, there is a definite lack of predictive biomarkers for response and/or tolerance to abemaciclib, which is important for patient selection. Another problem is that its contribution to overall survival (OS) has not been shown. And while two large the phase 3 study highlighted the anti-tumour effect of abemaciclib, the OS results are awaited. Furthermore, the effect on brain metastases is expected to be unique to abemaciclib as the response of brain metastasis in HR-positive breast cancer patients has been confirmed in a few cases with case collection still ongoing.